Immunic (IMUX) Saham Harga
Immunic Harga
Target harga median analis adalah 20,50 USD, di atas harga saat ini sebesar 164,5%. Dari 19 analis, 18 merekomendasikan beli — konsensus keseluruhan Beli.
Harga saham Immunic
Akses data ini lewat Eulerpool API
100.000 permintaan/bulan gratis · tanpa kartu
Model bisnis dan analisis saham Immunic
Pertanyaan yang sering diajukan tentang saham Immunic
Immunic Inc is primarily present in the United States.
Immunic Inc represents a strong commitment to advancing the treatment of autoimmune diseases and chronic inflammatory conditions. The company's corporate philosophy is centered around pioneering innovative therapies that address unmet medical needs, backed by extensive research and development. Immunic Inc prioritizes patient-centricity, aiming to enhance quality of life through effective and safe treatment options. With a focus on excellence and scientific rigor, Immunic Inc strives to deliver groundbreaking therapies that can make a meaningful difference in patients' lives.
The business model of Immunic Inc. is focused on developing innovative therapies for chronic inflammatory and autoimmune diseases. The company aims to leverage its deep understanding of the immune system and expertise in small molecule drug development to create potential treatments that target specific diseases. Through its research and development efforts, Immunic Inc. seeks to address unmet medical needs and improve the lives of patients suffering from a range of disorders, including ulcerative colitis, Crohn's disease, multiple sclerosis, and psoriasis. By combining scientific knowledge with a patient-centered approach, the company strives to provide effective and accessible therapies in the field of immunology.
Immunic Inc is primarily active in the pharmaceutical industry.
The main competitors of Immunic Inc in the market are [insert competitor names here].
Immunic Inc. is a pharmaceutical company specializing in the development of innovative therapies for autoimmune diseases and chronic inflammatory disorders. Founded in 2016, Immunic Inc. has quickly emerged as a key player in the field. The company is focused on leveraging its expertise in small molecule drug development to address unmet medical needs. Immunic Inc. is committed to advancing its pipeline of potential treatments, utilizing a targeted approach to modulate the immune system and provide patients with novel therapeutic options. With a strong dedication to research and development, Immunic Inc. aims to make a significant impact on patients' lives and contribute to the advancement of healthcare.
Immunic Inc, a leading biopharmaceutical company, has reached several significant milestones. Firstly, the company successfully completed a Phase 2 clinical trial for its novel therapeutic candidate, IMU-838, in patients with relapsing-remitting multiple sclerosis. The encouraging results demonstrated its potential in reducing disease activity and progression. Additionally, Immunic Inc achieved the initiation of Phase 2 clinical trials for IMU-935, an orally available small molecule targeting chronic inflammatory and autoimmune diseases. These milestones represent the company's commitment to developing innovative therapies addressing unmet medical needs. Immunic Inc continues to advance its pipeline, striving to provide effective treatments for patients globally.
Analis saat ini menetapkan target harga rata-rata 22,13 USD untuk saham Immunic (median: 20,50 USD), yaitu +185,5 % terhadap harga terbaru. Konsensus didasarkan pada 19 peringkat analis.
19 analis saat ini menilai saham Immunic: 18 merekomendasikan beli, 1 tahan, dan 0 jual. Untuk 2026, analis memperkirakan Immunic menghasilkan pendapatan 12,50 Juta. USD dan laba per saham -35,92 USD.
Dengan kurs saat ini, saham Immunic diperdagangkan pada 6,94 EUR (7,75 USD).
Saham Immunic (IMUX) tercatat di 5 bursa, termasuk: NASDAQ (IMUX), Frankfurt (10VA.F), München (10VA.MU), Düsseldorf (10VA.DU).
Immunic Inc is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for the treatment of immune and inflammatory diseases.The company's business model is based on four main pillars: research and development, clinical studies, product distribution, and partnerships.
Pendapatan diperkirakan dari Immunic adalah 12,50 Juta. USD. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.
Laba diperkirakan dari Immunic adalah -432,40 Juta. USD. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.
Rasio harga-terhadap-pendapatan (PER) Immunic saat ini adalah -0,22. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham Immunic.
Rasio harga-terhadap-penjualan (PSR) Immunic saat ini adalah 7,46. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham Immunic.
Skor Kualitas AlleAktien untuk Immunic adalah 5/10.
ISIN dari Immunic adalah US4525EP1011. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.
WKN dari Immunic adalah A2PHD4. WKN (Wertpapierkennnummer) adalah kode identifikasi sekuritas Jerman enam digit.
Ticker dari Immunic adalah IMUX. Simbol ticker digunakan untuk memperdagangkan saham Immunic di bursa saham.
Saham Immunic
Kelompok Peer Immunic
Immunic Ticker
Immunic FIGI
Semua metrik fundamental dan analisis mendalam Immunic
Analisis saham kami untuk saham Immunic mencakup kalkulasi keuangan penting seperti pendapatan, keuntungan, P/E ratio (P/E), P/S ratio (P/S), EBIT, serta informasi tentang dividen. Selain itu, kami juga mengamati aspek-aspek seperti saham, kapitalisasi pasar, utang, ekuitas, dan kewajiban dari Immunic. Jika Anda mencari informasi lebih rinci tentang topik-topik ini, kami menawarkan analisis terperinci di subhalaman kami.